

IN THE CLAIMS

1. (currently amended) A method of optimizing clinical diagnosis of a disease using a disease-specific diagnostic algorithm in a programmable automation system which allows the system to self-monitor after performing a clinical test, select the next appropriate test based upon the results obtained, and eliminate unnecessary tests, said method comprising the steps of:

- a) submitting patient tests ordered by a physician to a clinical lab,
- b) selecting a disease specific algorithm for tests necessary for clinical chemical analysis of a suspected disease or any one of subgroups of the disease,
- c) classifying the various subgroups of the suspected disease, said classification based on pathology, pathogenic agent, cause and symptoms,
- d) defining the relevant clinical tests suitable for diagnosing each of the subgroups of the suspected disease classified in c) and not allowing a technician to add unnecessary tests;
- e) carrying out only the relevant tests defined in d) to obtain at least one clinical test value;
- f) sequentially running [[the relevant]] a second set of clinical

tests for each of the sub-groups of the suspected disease upon receiving a first set of said clinical test values, and computing ~~[[the next]]~~ a second set of said clinical tests for further testing, and

- g) repeating steps e) and f) by self-monitoring of the system until ~~[[a complete]]~~ an optimized diagnosis of the specific suspected disease type and group is provided, thereby avoiding unnecessary clinical tests and expensive duplicative procedures, while enabling an accurate diagnosis using the disease-specific diagnostic algorithm.

2. (currently amended) The method of claim 1, further comprising performing a different clinical test from tests carried out in steps d) through e) after the values for the tests in steps d) through e) are ~~[[last clinical test is]]~~ negative, to rule out a different diagnosis.

3. (previously presented) The method of claim 1, further comprising running a program code to implement the diagnostic algorithm.

4. (currently amended) The method of claim 3, further comprising using a modified computer architecture code necessary to implement any modifications made in the diagnostic algorithm and ~~[[code]]~~ method of claim 3.

5. (withdrawn) The method according to claim 1, where said method is the acid fast bacteria algorithm comprising the steps of:

- a) defining the clinical tests used for the diagnosis of acid-fast bacteria;
 - b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;
 - c) sequentially reading out each of said clinical test normal values provided in b);
 - d) upon receiving a first of said clinical test values, computing the next set of said clinical tests for further testing, wherein the first of said clinical test values includes auramine smear and the next set of said clinical tests includes amplification; and
 - e) receiving a next one of said clinical test, wherein the next of said clinical tests includes organism identification by DNA probe or biochemicals.
6. (withdrawn) The method according to claim 1, wherein said method is the anemia algorithm comprising the steps of:
- a) defining the clinical tests used for the diagnosis of anemia, including myelodysplasia, leukemia, iron deficiency, or B-12/folate deficiency;
 - b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;

- c) sequentially reading out each of said clinical test normal values provided in b) ; and
 - d) upon receiving a first of said clinical test values, computing the next set of said clinical tests for further testing, wherein the first of said clinical test values include WBC, MCV, ferritin, B12/folate and the next set of said clinical tests includes smear/image or reticulocyte count, hemoglobin ID, B-12 or folate respectively.
7. (withdrawn) The method according to claim 1, wherein said method is the cardiac risk algorithm comprising the steps of:
- a) defining the clinical tests used for the diagnosis of cardiac risk, including abnormalities in cholesterol, triglycerides, LDL, HDL, homocysteine or anti-cardiolipn;
 - b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;
 - c) sequentially reading out each of said clinical test normal values provided in b) ; and
 - d) upon receiving a first of said clinical test values, computing the next set of said clinical tests for further testing, wherein the first of said clinical test values include cholesterol, HDL, triglycerides and the next set of said clinical tests includes

homocysteines anticardio- lipin antibody, LDL by calculation
or LDL by direct assay.

8. (withdrawn) The method of claim 1, wherein said method is the HbsAg algorithm comprising the steps of:
 - a) defining the clinical tests used for the diagnosis of HbsAG;
 - b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;
 - c) sequentially reading out each of said clinical test normal values provided in b) ; and
 - d) upon receiving a first of said clinical test values, computing the next set of said clinical test for further testing, wherein the first of said clinical test values include prenatal and dialysis specimen measurements of hepatitis B.
9. (withdrawn) The method according to claim 1, wherein said method is the breast cancer algorithm comprising the steps of:
 - a) defining the clinical tests used for the diagnosis of breast cancer including genetic markers;
 - b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;

- c) sequentially reading out each of said clinical test normal values provided in b) ; and
 - d) upon receiving a first of said clinical test values, computing the next set of said clinical test for further testing, wherein the first of said clinical test values include cancer marker 15-3, or cancer marker 27-29 and the next set of said clinical tests includes serum bone marker.
10. (withdrawn) The method according to claim 1, wherein said method is the prostate cancer algorithm comprising the steps of:
- a) defining the clinical tests used for the diagnosis of prostate cancer including PSA for no risk, equivocal risk or positive cancer;
 - b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;
 - c) sequentially reading out each of said clinical test normal values provided in b); and
 - d) upon receiving a first of said clinical test values, computing the next set of said clinical tests for further testing wherein the first of said clinical test values include PSA (total) and the next set of said clinical tests includes free PSA or serum bone marker.

11. (withdrawn) The method according to claim 1, wherein said method is the Epstein-Barr virus algorithm comprising the steps of:

- a) defining the clinical tests used for the diagnosis of Epstein-Barr virus, including viral capsid antigen, or Epstein Barr-Virus;
- b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;
- c) sequentially reading out each of said clinical test normal values provided in b); and
- d) upon receiving a first of said clinical test values, computing the next set of said clinical tests for further testing wherein the first of said clinical test values include anti-EBV early antigen D, and the next set of said clinical tests includes anti VCA and EBNA.

12. (cancelled)

13. (withdrawn) The method according to claim 1, wherein said method is the thyroid function algorithm comprising the steps of:

- a) defining the clinical tests used for the diagnosis of thyroid dysfunction;

- b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;
 - c) sequentially reading out each of said clinical test normal values provided in b);
 - d) upon receiving a first of said clinical test values, computing the next set of said clinical tests for further testing, wherein the first of said clinical test values include TSH and the next set of said clinical tests includes FT-3 or FT-4.
14. (withdrawn) The method according to claim 1, wherein said method is the autoimmune algorithm comprising the steps of:
- a) defining the clinical tests used for the diagnosis of autoimmune disease including lupus;
 - b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;
 - c) sequentially reading out each of said clinical test normal values provided in b);
 - d) upon receiving a first of said clinical test values, computing the next set of said clinical tests for further testing, wherein the first of said clinical test values include ANA and the next set of

said clinical tests includes ds-DNA, HISTONE, Sm
respectively, and

- e) receiving a next one of said clinical test of said data word,
wherein the next of said clinical tests includes SCL-70, RNP,
SSA, SSB, SS-DNA.

15. (withdrawn) The method according to claim 1, wherein said method
is the serum protein algorithm comprising the steps of:

- a) defining the clinical tests used for the diagnosis of serum
protein defect including serum protein electrophoresis;
- b) defining each of the clinical tests listed in (a) and providing
the normal value of each clinical test;
- c) sequentially reading out each of said clinical test normal
values provided in b) ; and
- d) upon receiving a first of said clinical test values, computing
the next set of said clinical tests for further testing, wherein the
first of said clinical test values include serum immuno fixation
electrophoresis and the next set of said clinical tests includes
quantitative assay of immuno globulin identified by SIFE.

16. (withdrawn) The method according to claim 1, wherein said method
is the urinalysis algorithm comprising the steps of:

- a) defining the clinical tests used for the diagnosis urine abnormalities;
- b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;
- c) sequentially reading out each of said clinical test normal values provided in b); and
- d) upon receiving a first of said clinical test values, computing the next set of said clinical tests for further testing, wherein the first of said clinical test values include protein, blood, leukocyte esterase ornitrite and the next set of said clinical tests includes microscopic examination of urine.

17. (withdrawn) The method according to claim 1, wherein said method is the human immunodeficiency algorithm comprising the steps of:

- a) defining the clinical tests used for the diagnosis of human immunodeficiency virus;
- b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;
- c) sequentially reading out each of said clinical test normal values provided in b);

- d) upon receiving a first of said clinical test values, computing the next set of said clinical tests for further testing, wherein the first of said clinical test values include HIV-1 and the next set of said clinical tests includes HIV-1 and HIV-2 respectively, and
 - e) receiving a next one of said clinical test of said data word, wherein the next of said clinical tests includes HIV-2 WB.
- 18. (cancelled).
- 19. (withdrawn) The method according to claim 1, wherein said method is the syphilis algorithm comprising the steps of:
 - a) defining the clinical tests used for the diagnosis of syphilis;
 - b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;
 - c) sequentially reading out each of said clinical test normal values provided in b) ; and
 - d) upon receiving a first of said clinical test values, computing the next set of said clinical test for further testing, wherein the first of said clinical test values include Elisa for T. Pallidum, and the next set of said clinical tests includes repeat Elisa and the rapid plasma regain test.

20. (withdrawn) The method according to claim 1, wherein said method is the thrombophilia algorithm comprising the steps of:
- a) defining the clinical tests used for the diagnosis of thrombophilia including LA/APA Alg(+) or APC-R(+);
 - b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;
 - c) sequentially reading out each of said clinical test normal values provided in b;
 - d) upon receiving a first of said clinical test values, computing the next set of said clinical tests for further testing, wherein the first of said clinical test values include LA-APA Alg(+) or APC-R(+) and the next set of said clinical tests includes homocysteine CRP; and
 - e) receiving a next one of said clinical test of said data word, wherein the next of said clinical tests includes Protein C, Protein S or AT-11.
21. (previously presented) A system for optimizing clinical diagnosis of a disease using a diagnostic algorithm, said system being computer implemented and comprising:

- a) a memory storing component, said component used for storing a set of m clinical tests;
- b) means of selecting tests necessary to diagnose a suspected disease from tests ordered by a physician;
- c) means for sequentially reading out each of m clinical tests from said memory, wherein m is an integer greater than one;
- d) a processor for sequentially programming each of the m clinical tests to produce a complete diagnosis, and for outputting the result.

22. (cancelled)

23. (previously presented) The system of claim 21, wherein the memory comprises an array of chips, each of which includes a plurality of m -bit storage cells.

24. (currently amended) The system of claim 23, wherein m equals [[at least]] to one.

25. (withdrawn) The method according to claim 1, wherein said method is the lupus algorithm comprising the steps of:

- a) defining the clinical tests for diagnosis of lupus anticoagulant/APA;

- b) defining each of the clinical tests listed in (a) and providing the normal value of each clinical test;
- c) sequentially reading out each of said clinical test normal values provided in b); and
- d) upon receiving a first of said clinical test values, computing the next set of said clinical tests for further testing, wherein the first of said clinical test values include DRVFT and the next set of said clinical tests includes LAC.
- e) from said memory; and
- f) upon receiving a first of said clinical test values, computing the next set of said clinical tests for further testing, wherein the first of said clinical test values include WBC, MCV, ferritin, B12/folate and the next set of said clinical tests includes smear/image or reticulocyte count, hemoglobin ID, B-12 or folate respectively.

26. (currently amended) The method of claim 1, wherein the disease-specific diagnostic algorithm comprises [[the]] a Hepatitis Algorithm.

27. (currently amended) The method according to claim 1, wherein said method is [[the]] a hepatitis B algorithm comprising the steps of:

- a) defining the clinical tests used for the diagnosis of hepatitis B, including HBsAg, HBsAb or SGPT;
- b) defining each of the clinical tests for hepatitis B listed in (a) and providing the normal value of each clinical test;
- c) sequentially reading out each of said clinical test normal values provided in b);
- d) upon receiving a first of said clinical test values, computing [[the next]] a second set of said clinical tests in the diagnostic algorithm for further testing, wherein the first of said clinical test values include HBsAg(+), HBsAg(-)/HBsAb(+) or HBsAg(-)/HBsAb(-), and the [[next]] second set of said clinical tests includes AFP/HBeAg/Ab, Immune or Hepatitis B(-) respectively,
- e) receiving a [[next one]] third set of said clinical tests, wherein the [[next]] third set of said clinical tests includes HBe Ab
- f) computing a next portion of the diagnostic algorithm using [[said next]] a fourth set of said clinical tests and a most recently calculated value of a computation of a prior portion of the diagnostic algorithm to produce a [[second]] fourth clinical test value; and

if necessary, repeating steps (e) and (f) until all of said clinical tests have been processed, wherein the final value computed for the last clinical test is a value for the complete diagnosis of hepatitis B.